76 related articles for article (PubMed ID: 20393402)
1. Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients.
Torregrosa JV; Fuster D; Gentil MA; Marcen R; Guirado L; Zarraga S; Bravo J; Burgos D; Monegal A; Muxí A; García S
Transplantation; 2010 Jun; 89(12):1476-81. PubMed ID: 20393402
[TBL] [Abstract][Full Text] [Related]
2. Weekly risedronate in kidney transplant patients with osteopenia.
Torregrosa JV; Fuster D; Pedroso S; Diekmann F; Campistol JM; Rubí S; Oppenheimer F
Transpl Int; 2007 Aug; 20(8):708-11. PubMed ID: 17555530
[TBL] [Abstract][Full Text] [Related]
3. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
Reid DM; Hughes RA; Laan RF; Sacco-Gibson NA; Wenderoth DH; Adami S; Eusebio RA; Devogelaer JP
J Bone Miner Res; 2000 Jun; 15(6):1006-13. PubMed ID: 10841169
[TBL] [Abstract][Full Text] [Related]
5. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
6. Changes in bone mineral density and selected metabolic parameters over 24 months following renal transplantation.
Al-Gabri S; Zadrazil J; Krejcí K; Horák P; Bachleda P
Transplant Proc; 2005 Mar; 37(2):1014-9. PubMed ID: 15848609
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
8. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D
Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
10. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Cohen S; Levy RM; Keller M; Boling E; Emkey RD; Greenwald M; Zizic TM; Wallach S; Sewell KL; Lukert BP; Axelrod DW; Chines AA
Arthritis Rheum; 1999 Nov; 42(11):2309-18. PubMed ID: 10555025
[TBL] [Abstract][Full Text] [Related]
11. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
Watts NB; Geusens P; Barton IP; Felsenberg D
J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Brown JP; Kendler DL; McClung MR; Emkey RD; Adachi JD; Bolognese MA; Li Z; Balske A; Lindsay R
Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
[TBL] [Abstract][Full Text] [Related]
13. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
14. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).
Fujii N; Hamano T; Mikami S; Nagasawa Y; Isaka Y; Moriyama T; Horio M; Imai E; Hori M; Ito T
Nephrol Dial Transplant; 2007 Jun; 22(6):1601-7. PubMed ID: 17124283
[TBL] [Abstract][Full Text] [Related]
15. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
[TBL] [Abstract][Full Text] [Related]
16. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
[TBL] [Abstract][Full Text] [Related]
17. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study.
Marcén R; Caballero C; Pascual J; Teruel JL; Tenorio M; Ocaña J; Villafruela JJ; Burgos FJ; Fernández AM; Muriel A; Ortuño J
Transplantation; 2006 Mar; 81(6):826-31. PubMed ID: 16570003
[TBL] [Abstract][Full Text] [Related]
18. Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomised study.
Kinov P; Tivchev P; Doukova P; Leithner A
Acta Orthop Belg; 2006 Jan; 72(1):44-50. PubMed ID: 16570894
[TBL] [Abstract][Full Text] [Related]
19. The effect of low-dose cholecalciferol and calcium treatment on posttransplant bone loss in renal transplant patients: a prospective study.
Sahin G; Yasar NS; Sirmagul B; Bal C; Yalcin AU
Ren Fail; 2008; 30(10):992-9. PubMed ID: 19016151
[TBL] [Abstract][Full Text] [Related]
20. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
